Escitalopram and Language Intervention for Subacute Aphasia
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Aphasia, Stroke
In brief
In this project, the investigators will investigate the effects of a selective serotonin reuptake inhibitor (SSRI), escitalopram, on augmenting language therapy effectiveness, as measured by naming untrained pictures and describing pictures, in individuals with aphasia in the acute and subacute post stroke period (i.e., within three months post stroke).
Key facts
- Study ID
- NCT03843463
- Run by
- Johns Hopkins University
- People needed
- 88
- Starts
- 2021-07-18
- Expected to finish
- 2027-01-18
- Last updated by the study team
- 2025-09-23
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have sustained an acute ischemic left hemisphere stroke.
- Participants must be fluent speakers of English by self-report.
- Participants must be capable of giving informed consent or indicating a legally authorized representative to provide informed consent.
- Participants must be age 18 or older.
- Participants must be within 5 days of onset of stroke.
- Participants must be pre-morbidly right-handed by self-report.
- Participants must have an aphasia diagnosis as confirmed by the Western Aphasia Battery-Revised (Aphasia Quotient < 93.8).
You may not qualify if…
- Previous neurological disease affecting the brain including previous symptomatic stroke
- Diagnosis of schizophrenia, autism, or other psychiatric or neurological condition that affects naming/language
- A history of additional risk factors for torsades de pointes (TdP; e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- Current severe depression, defined as a score of > 15 on the Patient Health Questionnaire (PHQ-9)
- Uncorrected visual loss or hearing loss by self-report
- Use of any medication approved by the FDA for treatment of depression at the time of stroke onset
- Concomitant use of any monoamine oxidase inhibitors (MAOIs) or pimozide, or other drugs that prolong the QT/QTc interval, triptans (and other 5-Hydroxytryptamine Receptor Agonists), or other contraindications to escitalopram that may be identified.
- A QTc greater than 450 milliseconds on electrocardiogram or evidence of hyponatremia (Na < 130) at baseline
- Pregnancy at the time of stroke or planning to become pregnant during the study term.
Where it is running
- Johns Hopkins School of Medicine — Baltimore, Maryland, United States (enrolling)
- Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
- University of South Carolina — Columbia, South Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.